Mutual Funds

Invesco Global Health Care Fund

Equity | Sector Equity

Objective & Strategy

The fund seeks long-term growth of capital by investing in equity securities of health care companies throughout the world.

Style Map

Invesco Global Health Care Fund

The map illustrates areas in which the fund can invest, not necessarily within a limited period of time. This fund is not classified with regard to one primary market capitalization.

as of 05/31/2015

Morningstar Rating

Overall Rating - Health Category

As of 05/31/2015 the Fund had an overall rating of 2 stars out of 123 funds and was rated 2 stars out of 123 funds, 2 stars out of 117 funds and 2 stars out of 97 funds for the 3-, 5- and 10- year periods, respectively.

Morningstar details

Source: Morningstar Inc. Ratings are based on a risk-adjusted return measure that accounts for variation in a fund's monthly performance (including the effect of sales charges, loads and redemption fees), placing more emphasis on downward variations and rewarding consistent performance. The overall rating is derived from a weighted average of three-, five- and 10-year rating metrics, as applicable. ©2015 Morningstar Inc. All rights reserved. The information contained herein is proprietary to Morningstar and/or its content providers. It may not be copied or distributed and is not warranted to be accurate, complete or timely. Neither Morningstar nor its content providers are responsible for any damages or losses arising from any use of this information. Past performance does not guarantee future results. A fund is eligible for a Morningstar Rating three years after inception. The top 10% of funds in a category receive five stars, the next 22.5% four stars, the next 35% three stars, the next 22.5% two stars and the bottom 10% one star. (Each share class is counted as a fraction of one fund within this scale and rated separately, which may cause slight variations in the distribution percentages.) Ratings for other share classes may differ due to different performance characteristics.

Management team

as of 05/31/2015

Top Equity Holdings | View all

% of Total Assets
ACTAVIS PLC 4.79
SHIRE PLC ADR 4.10
NOVARTIS AG ADR 3.81
GLAXOSMITHKLINE PLC ADR 3.34
ROCHE HOLDING AG GENUSSS 3.33
ABBVIE INC 3.26
MERCK & CO INC 2.61
GILEAD SCIENCES INC 2.54
PFIZER INC 2.51
BRISTOL MYERS SQUIBB CO 2.37

Holdings are subject to change and are not buy/sell recommendations.

as of 05/31/2015 03/31/2015

Average Annual Returns (%)

  Incept.
Date
Max
Load (%)
Since
Incept. (%)
YTD (%) 1Y (%) 3Y (%) 5Y (%) 10Y (%)
NAV 08/07/1989 N/A 12.06 12.19 27.99 29.79 21.65 11.60
Load 08/07/1989 5.50 11.81 6.01 20.95 27.37 20.29 10.97
Performance quoted is past performance and cannot guarantee comparable future results; current performance may be lower or higher. Investment return and principal value will vary so that you may have a gain or a loss when you sell shares.

Performance shown at NAV does not include applicable front-end or CDSC sales charges, which would have reduced the performance.

Performance figures reflect reinvested distributions and changes in net asset value (NAV) and the effect of the maximum sales charge unless otherwise stated.

as of 05/31/2015

Annualized Benchmark Returns


Index Name 1 Mo (%) 3 Mo (%) 1Y (%) 3Y (%) 5Y (%) 10Y (%)
MSCI Wld Hlth Cr ND IX 2.83 4.04 21.36 27.13 21.20 10.19
MSCI World IX ND 0.34 1.09 5.70 17.09 12.84 6.72
N/A N/A N/A N/A N/A N/A
N/A N/A N/A N/A N/A N/A

Source: FactSet Research Systems Inc.

Source: FactSet Research Systems Inc.

An investment cannot be made directly in an index.

Expense Ratio per Prospectus

Management Fee 0.62
12b-1 Fee 0.25
Other Expenses 0.21
Interest/Dividend Exp 0.00
Total Other Expenses 0.21
Acquired Fund Fees and Expenses (Underlying Fund Fees & Expenses) 0.01
Total Annual Fund Operating Expenses 1.09
Contractual Waivers/Reimbursements -0.01
Net Expenses - PER PROSPECTUS 1.08
Additional Waivers/Reimbursements 0.00
Net Expenses - With Additional Fee Reduction 1.08
This information is updated per the most recent prospectus.

Historical Prices

From   to
No history records found for this date range

Distributions

From   to
    Capital Gains Reinvestment
Price ($)
Ex-Date Income Short Term Long Term
12/12/2014 N/A 0.0070 4.9235 42.59
12/13/2013 0.0126 0.2353 3.2195 38.12
09/19/2013 0.0508 N/A N/A 40.00
12/07/2012 0.1229 N/A 2.2410 30.41
12/09/2011 0.1436 N/A 0.4830 26.76
12/12/2008 N/A N/A 0.6010 18.95
12/14/2007 N/A 0.7152 2.1662 28.89
12/15/2006 N/A N/A 3.0024 28.633
12/16/2005 N/A N/A 0.9343 30.285
12/14/2001 N/A 1.5474 2.5111 26.741
12/14/2000 N/A 1.1363 2.1083 28.079
12/15/1999 N/A N/A 2.2827 22.058
12/08/1997 N/A 5.1450 1.5670 20.77
12/03/1996 N/A 1.8500 N/A 22.37
12/15/1995 N/A 0.4000 2.4600 20.64
12/05/1994 N/A N/A 1.3400 17.62
12/20/1993 0.0620 N/A N/A 18.50
12/20/1991 N/A N/A 0.1400 19.59
12/14/1990 0.1590 N/A 0.1910 13.68
12/19/1989 0.0300 N/A N/A 12.01
as of 05/31/2015

Sector Breakdown

The holdings are organized according to the Global Industry Classification Standard, which was developed by and is the exclusive property and a service mark of Morgan Stanley Capital International Inc. and Standard & Poor's.

as of 05/31/2015

Fund Characteristics

3-Year Alpha 1.04%
3-Year Beta 1.05
3-Year R-Squared 0.81
3-Year Sharpe Ratio 2.90
3-Year Standard Deviation 10.26
Number of Securities 80
Total Assets $2,058,552,200.00
Wghtd Med Mkt Cap MM$ $52,055.00

Source: FactSet Research Systems Inc., StyleADVISOR

Benchmark:  MSCI Wld Hlth Cr ND IX

as of 05/31/2015

Top Equity Holdings | View all

% of Total Assets
ACTAVIS PLC 4.79
SHIRE PLC ADR 4.10
NOVARTIS AG ADR 3.81
GLAXOSMITHKLINE PLC ADR 3.34
ROCHE HOLDING AG GENUSSS 3.33
ABBVIE INC 3.26
MERCK & CO INC 2.61
GILEAD SCIENCES INC 2.54
PFIZER INC 2.51
BRISTOL MYERS SQUIBB CO 2.37

Holdings are subject to change and are not buy/sell recommendations.

as of 05/31/2015

Top Industries

  % of Total Assets
Pharmaceuticals 49.20
Biotechnology 25.54
Health Care Equipment 4.47
Health Care Facilities 4.11
Managed Health Care 3.83
Health Care Distributors 2.46
Health Care Services 2.25
Life Sciences Tools & Services 1.90
Drug Retail 1.48
Health Care Technology 0.98

The holdings are organized according to the Global Industry Classification Standard, which was developed by and is the exclusive property and a service mark of Morgan Stanley Capital International Inc. and Standard & Poor's.

as of 05/31/2015

Top Countries

  % of Total Assets
United States 61.00
Ireland 11.74
Switzerland 7.14
United Kingdom 6.53
France 2.83
Germany 2.15
Japan 2.02
Israel 1.89
Brazil 0.72
Canada 0.20

 About risk

Convertible Securities Risk. The Fund may own convertible securities, the value of which may be affected by market interest rates, the risk that the issuer will default, the value of the underlying stock or the right of the issuer to buy back the convertible securities.

Depositary Receipts Risk. Depositary receipts involve many of the same risks as those associated with direct investment in foreign securities. In addition, the underlying issuers of certain depositary receipts, particularly unsponsored or unregistered depositary receipts, are under no obligation to distribute shareholder communications to the holders of such receipts or to pass through to them any voting rights with respect to the deposited securities.

Derivatives Risk. The value of a derivative instrument depends largely on (and is derived from) the value of an underlying security, currency, commodity, interest rate, index or other asset (each referred to as an underlying asset). In addition to risks relating to the underlying assets, the use of derivatives may include other, possibly greater, risks, including counterparty, leverage and liquidity risks. Counterparty risk is the risk that the counterparty to the derivative contract will default on its obligation to pay the Fund the amount owed or otherwise perform under the derivative contract. Derivatives create leverage risk because they do not require payment up front equal to the economic exposure created by owning the derivative. As a result, an adverse change in the value of the underlying asset could result in the Fund sustaining a loss that is substantially greater than the amount invested in the derivative, which may make the Fund's returns more volatile and increase the risk of loss. Derivative instruments may also be less liquid than more traditional investments and the Fund may be unable to sell or close out its derivative positions at a desirable time or price. This risk may be more acute under adverse market conditions, during which the Fund may be most in need of liquidating its derivative positions. Derivatives may also be harder to value, less tax efficient and subject to changing government regulation that could impact the Fund's ability to use certain derivatives or their cost. Also, derivatives used for hedging or to gain or limit exposure to a particular market segment may not provide the expected benefits, particularly during adverse market conditions.

Developing/Emerging Markets Securities Risk. The prices of securities issued by foreign companies and governments located in developing/emerging markets countries may be affected more negatively by inflation, devaluation of their currencies, higher transaction costs, delays in settlement, adverse political developments, the introduction of capital controls, withholding taxes, nationalization of private assets, expropriation, social unrest, war or lack of timely information than those in developed countries.

Foreign Securities Risk. The Fund's foreign investments may be affected by changes in a foreign country's exchange rates, political and social instability, changes in economic or taxation policies, difficulties when enforcing obligations, decreased liquidity, and increased volatility. Foreign companies may be subject to less regulation resulting in less publicly available information about the companies.

Geographic Focus Risk. From time to time the Fund may invest a substantial amount of its assets in securities of issuers located in a single country or a limited number of countries. If the Fund focuses its investments in this manner, it assumes the risk that economic, political and social conditions in those countries will have a significant impact on its investment performance. The Fund's investment performance may also be more volatile if it focuses its investments in certain countries, especially emerging markets countries.

Health Care Sector Risk. The Fund will concentrate its investments in the securities of domestic and foreign issuers in the health care industry. The Fund's performance is vulnerable to factors affecting the health care industry, including government regulation, obsolescence caused by scientific advances and technological innovations.

Management Risk. The investment techniques and risk analysis used by the Fund's portfolio managers may not produce the desired results.

Market Risk. The prices of and the income generated by the Fund's securities may decline in response to, among other things, investor sentiment, general economic and market conditions, regional or global instability, and currency and interest rate fluctuations.

Preferred Securities Risk. There are special risks associated with investing in preferred securities. Preferred securities may include provisions that permit the issuer, in its discretion, to defer or omit distributions for a certain period of time. If the Fund owns a security that is deferring or omitting its distributions, the Fund may be required to report the distribution on its tax returns, even though it may not have received this income. Further, preferred securities may lose substantial value due to the omission or deferment of dividend payments.

Small- and Mid-Capitalization Risks. Stocks of small- and mid-sized companies tend to be more vulnerable to adverse developments and may have little or no operating history or track record of success, and limited product lines, markets, management and financial resources. The securities of small- and mid-sized companies may be more volatile due to less market interest and less publicly available information about the issuer. They also may be illiquid or restricted as to resale, or may trade less frequently and in smaller volumes, all of which may cause difficulty when establishing or closing a position at a desirable price.

as of 06/30/2015

GGHCX

NAV Change ($)
$47.92 0.59
N/As may appear until data is available. Data is usually updated between 3 and 6 p.m. CST.

Fund Details

  • Distribution Frequency Annually
  • NASDAQ GGHCX
  • WSJ Abrev. GlHltCr
  • CUSIP 00141T106
  • Fund Type Equity
  • Geography Type Global
  • Inception Date 08/07/1989
  • Fiscal Year End 10/31
  • Min Initial Investment $1,000
  • Subsequent Investment $50
  • Min Initial IRA Investment $250
  • Fund Number 1551
  • Tax ID 93-1006889

Exclusive Materials

Additional materials may be available for registered users. Please log in for full access.

Exclusive Materials

Additional materials may be available for registered users. Please log in for full access.